Encompass Health heads into its August 5 earnings update with a striking reversal in options sentiment — one that directly contradicts the bullish positioning seen just days ago ahead of its Q2 print.
The shift is sharp and recent. The put/call ratio has collapsed to 0.34, nearly two standard deviations below its 20-day average of 0.84 — but that average is now being dragged down by the extreme call-heavy readings from late July. Looking at the raw directional change, the PCR was running at 0.73 heading into the July 31 report, which itself was flagged as unusually bullish. It has pushed even lower since, hitting a near-term low of 0.33 on July 28-29. Call demand remains dominant, and the 52-week low on the PCR is 0.08 — so there is room further in this direction. The stock has pulled back modestly from the post-Q2 highs, down 1.6% on the week to $111.07, after a strong month that added nearly 10%. The borrow market remains entirely unthreatening: availability is vast at over 2,600% of short interest, and cost to borrow is negligible at 0.38%.
Short interest tells a more cautious story underneath the surface calm. Bears added positions at an accelerating pace through late July — SI climbed nearly 18% over the past week to 3.9% of the free float, continuing a trend that has now pushed the short base up 16% in a month. That build started before the Q2 result was known, and it has continued after. At 3.9% of float with borrow this loose, it does not represent extreme conviction — but the direction of travel is consistent and warrants watching. The ORTEX short score has drifted higher every session this week, reaching 38.2, up from 34.8 ten days ago, though it remains well below levels that historically signal a crowded short.
The analyst community remains firmly constructive. Eleven of the covering firms carry buy-equivalent ratings, with a consensus target of $141 — implying roughly 27% upside from current levels. TD Cowen initiated with a Buy and a $125 target in late May, while Barclays trimmed its target from $153 to $140 after Q1 results while keeping its Overweight rating — a signal of slightly tempered enthusiasm rather than a change in direction. The bull case centres on revenue guidance momentum and a growing Medicare Advantage mix now approaching 17% of the payer book. Bears point to execution risk around the company's de novo facility expansion programme, where construction costs, staffing challenges, and tariff pressures could weigh on EBITDA delivery against the $1.245 billion 2025 target. EHC has a strong recent track record of beating estimates — the EPS surprise factor ranks in the 81st percentile — and the last three earnings events each produced positive one-day moves ranging from 1% to 6.6%.
The August 5 print will test whether that consistency holds when the market's attention has already shifted from the last beat to what comes next on the expansion pipeline.
See the live data behind this article on ORTEX.
Open EHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
